Iovance Biotherapeutics shares are trading higher after UBS initiated coverage on the stock with a Buy rating and announced a price target of $17.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics shares rose following UBS's initiation of coverage with a Buy rating and a $17 price target.
October 24, 2024 | 2:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS initiated coverage on Iovance Biotherapeutics with a Buy rating and a $17 price target, leading to a rise in the stock price.
The initiation of coverage by UBS with a Buy rating and a specific price target of $17 is a positive signal to investors, likely increasing demand for the stock and driving up its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100